Tuberculosis vaccines: Hopes and hurdles

Infectious Disorders - Drug Targets

Volumn 13, Issue 5, 2013, Pages 318-321

  Ahsan, Mohamed J ^a   Garg, Shiv K ^a   Vashistha, Bharat ^a   Sharma, Piush ^a  

^a Maharishi Arvind Institute of Pharmacy   (India)

Author keywords

Clinical trials; Review; Tuberculosis; Tuberculosis vaccines

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS VACCINE; VIRUS VECTOR; LIVE VACCINE; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; IMMUNOTHERAPY; INDIA; MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM INDICUS PRANII; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; TUBERCULOSIS; VIRUS GENE; WHOLE CELL; COMPLICATION; DRUG DESIGN; HEALTH; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE;

ANTITUBERCULAR AGENTS; BCG VACCINE; DRUG DESIGN; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED;

EID: 84897581285     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526513666131201125513     Document Type: Article

References (19)

1. World Health Organization Global Tuberculosis Report 2012, ISBN 9789241564502.
2. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T, Churcher, C.; Harris, D.; Gordon, S.V.; Eiglmeier, K.; Gas, S.; Barry, C.E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G. Deciphering the biology of Mycobac-terium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-544.
3. Jefferys, R. The Tuberculosis Vaccine. In: 2012 Pipeline Report; Andrea Benzacar, Ed.; Treatment Action Group, New York, USA, 2012, 250-259.
4. Barry, C.E.; Boshoff, H.I.; Dartois, V.; Dick, T.; Ehrt, S.; Flynn, J.; Schnappinger, D.; Wilkinson, R.J.; Young, D. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat. Rev. Microbiol., 2009, 7, 845-855.
5. World Health Organization. The Stop TB Strategy: Building on and enhancing DOTS to meet the TB related Millennium Development Goals. Geneva: World Health Organization, 2006. Available at: http://www.who.int/tb/publications/2006/stop_tb_strategy.pdf. (Accessed on June 02, 2013).
6. Abu-Raddad, L.J.; Sabatelli, L.; Achterberg, J.T.; Sugimoto, J.D.; Longini, I.M.; Dye, C.; Halloran, M.E. Epidemiological benefits benefits of more effective tuberculosis vaccines, drugs and diagnostics. Proc. Natl. Acad. Sci., 2009, 106, 13980-13985.
7. Beresford, B.; Sadoff, J.C. Update on Research and Development Pipeline: Tuberculosis vaccines. Clin. Infect. Dis., 2010, 50(S3), S178-S183.
8. Ottenhoff, T.; Kaufmann, S. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathogens, 2012, 8(5), e1002607.
9. Progress in new TB vaccine development areas. Available at: http://www.c_path.org (Accessed on 24/08/2013).
10. Stop TB Partnership and the World Health Organization. Global Plan to Stop TB, 2011-2015: Transforming the Fight towards Elimination of Tuberculosis. Geneva: WHO; 2010. Available online from: http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf. (Accessed on 03/06/2013).
11. McShane, H. Tuberculosis vaccines: beyond bacilli Calmette-Guérin. Philos. Trans R. Soc. Lond. B. Biol. Sci., 2011, 366(1579), 2782-2789.
12. Frick, M. The Tuberculosis Vaccine. In 2012 Pipeline Report, Andrea Benzacar, Ed.; Treatment Action Group, NY, USA. 2012; pp. 262-283. ISBN 978-0-9837221-8-2.
13. TB vaccines pipeline 2011. Available at: http://www.stoptb.org. (Accessed on February 21, 2013).
14. Horwitz, M.A.; Harth, G.; Dillon, B.J.; Maslesa-Galic, S. Recom-binant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci., 2000, 97, 13853-13858.
15. Hoft, D.F.; Blazevic, A.; Abate, G.; Hanekom, W.A.; Kaplan, G.; Soler, J.S.; Weichold, F.; Geiter, L.; Sadoff, J.C.; Horwitz, M.A. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J. Infect. Dis., 2008, 198, 1491-1501.
16. Kamath, A.T; Fruth, U.; Brennan, M.J.; Dobbelaer, R.; Hubrechts, P.; Ho, M.M.; Mayner, R.E.; Thole, J.; Walker, K.B.; Liu, M.; Lambert, P.H.; AERAS Global TB vaccines Foundation.; World Health Organization. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine, 2005, 23, 3753-3761.
17. Grode, L.; Seiler, P.; Baumann, S.; Hess, J.; Brinkmann, V.; Ed-dine, A.N.; Mann, P.; Goosmann, C.; Bandermann, S.; Smith, D.; Bancroft, G.J.; Reyrat, J.M.; Soolingen, D.; Raupach, B.; Kauf-mann, S. H. E. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest., 2005, 115, 2472-2479.
18. Martin, C.; Williams, A.; Hernandez-Pando, R.; Cardona, P.J.; Gormley, E.; Bordat, Y.; Soto, C.Y.; Clark, S.O.; Hatch, G.J.; Aq-uilar, D.; Ausina, V.; Gicquel, B. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine, 2006, 24(17), 3408-19.
19. Soto, A.; Mene, M.; Samper, S.; Go, A.; Barcia, M.; Martin C. IS6100 mediates increased transcription of the phoP virulence gene in multidrug-resistant clinical isolate responsible for tuberculosis outbreaks. J. Clin. Microbiol., 2004, 42(1), 212-219.